deCODE Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?
This article was originally published in Start Up
deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.
You may also be interested in...
Polaris Partners: The 2013 A-List Investor Spotlight
Polaris’ focus on people and platforms was never more evident than in 2013, when it leveraged its relationship with one entrepreneur in particular to great effect.
Acadia, deCODE: Venture Bets On Comeback Kids Pay Off
Two long-in-the-tooth biotechs, Acadia and deCODE, were desperate for help. The venture investors who helped bail them out have seen their investments pay off nicely. Promising Phase III data for its lead compound have boosted Acadia’s stock, and Amgen spent generously to buy deCODE’s genetic expertise for its own drug discovery efforts.
Deals Of The Week: Teva/Xenon, Biogen Idec/Isis, Bristol-Myers Squibb/The Medicines Company
Amgen’s unexpected buyout of deCode Genetics means the founder’s expensive philosophy of focusing on pioneering science rather than quick-to-market products finally will pay off for the Icelandic firm’s venture capital backers.